摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(1R,2S,3R,5S)-2-((benzyloxy)methyl)-6-oxabicyclo[3.1.0]hexan-3-ol | 701278-59-3

中文名称
——
中文别名
——
英文名称
(1R,2S,3R,5S)-2-((benzyloxy)methyl)-6-oxabicyclo[3.1.0]hexan-3-ol
英文别名
Entecavir E2;(1R,2S,3R,5S)-2-(phenylmethoxymethyl)-6-oxabicyclo[3.1.0]hexan-3-ol
(1R,2S,3R,5S)-2-((benzyloxy)methyl)-6-oxabicyclo[3.1.0]hexan-3-ol化学式
CAS
701278-59-3
化学式
C13H16O3
mdl
——
分子量
220.268
InChiKey
LPHHAQDOQOLDFK-QNWHQSFQSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    363.1±22.0 °C(Predicted)
  • 密度:
    1.222±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.1
  • 重原子数:
    16
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.54
  • 拓扑面积:
    42
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Asymmetric Synthesis of Polyhydroxylated <i>N</i>-Alkoxypiperidines by Ring-Closing Double Reductive Amination: Facile Preparation of Isofagomine and Analogues
    作者:Gaëlle Malik、Xavier Guinchard、David Crich
    DOI:10.1021/ol203213f
    日期:2012.1.20
    A de novo synthesis of novel polyhydroxylated N-alkoxypiperidines based on the ring-closing double reductive amination of 1,5-dialdehydes, obtained by oxidative cleavage of cyclopentene derivatives, with O-substituted hydroxylamines is reported. Isofagomine was accessed by cleavage of the N–O bond of an N-alkoxypiperidine.
    报道了一种新的多羟基化的N-烷氧基哌啶的从头合成,该合成是基于通过用O-取代的羟胺环戊烯生物进行氧化裂解而得到的1,5-二醛的双环还原胺化。通过切割N-烷氧基哌啶的N-O键可访问异黄花碱。
  • Preparation process of an antiviral drug and intermediates thereof
    申请人:Esteve Química, S.A.
    公开号:EP2474548A1
    公开(公告)日:2012-07-11
    Preparation process of an antiviral drug and intermediates thereof It comprises a preparation process of entecavir comprising: submitting a (1S,3R)-3-(tert-butyldimethylsilyloxy)-1-(oxiran-2-yl)pent-4-yn-1-ol (VIII) to a double esterification and to a radicalary cyclization, yielding a compound of formula (V), where either a compound of formula (VIII) is submitted to a first esterification reaction, then to a catalytic radicalary cyclization using titanocene dichloride as catalyst in the presence of Mn/2,4,6-collidine HCl or Zn/2,4,6-collidine/trimethylsilyl chloride, and finally to a second esterification reaction or, alternatively, the compound of formula (VIII) is submitted first to a catalytic radicalary cyclization, and then to an esterification reaction. Entecavir can be obtained by submitting compound (V) to a desilylation reaction to remove the TBS group and then to a Mitsunobu coupling with 2-amino-6-chloroguanine, followed by hydrolysis. It also relates to some new intermediates of the process.
    抗病毒药物及其中间体的制备过程 本发明涉及一种恩替卡韦的制备过程,包括:将(1S,3R)-3-(叔丁基二甲基氧基)-1-(环氧丙烷-2-基)戊-4-炔-1-醇(VIII)进行双重酯化反应和自由基环化反应,得到公式(V)的化合物,其中化合物(VIII)先进行第一次酯化反应,然后使用二氯化钛作为催化剂,在Mn/2,4,6-共咪唑盐酸盐或Zn/2,4,6-共咪唑/三甲基氯硅烷的存在下进行催化自由基环化反应,最后进行第二次酯化反应;或者,另一种方法是将化合物(VIII)先进行催化自由基环化反应,然后进行酯化反应。恩替卡韦可以通过将化合物(V)进行去反应去除TBS基团,然后与2-基-6-氯鸟嘌呤进行Mitsunobu偶联反应,再经解反应制得。本发明还涉及该过程中的一些新型中间体。
  • [EN] PREPARATION PROCESS OF AN ANTIVIRAL DRUG (ENTECAVIR) AND INTERMEDIATES THEREOF<br/>[FR] PROCÉDÉ DE PRÉPARATION D'UN MÉDICAMENT ANTIVIRAL (ENTÉCAVIR) ET SES INTERMÉDIAIRES
    申请人:ESTEVE QUIMICA SA
    公开号:WO2012085209A1
    公开(公告)日:2012-06-28
    It comprises a preparation process of entecavir comprising: submitting a (1S, 3R)-3-(tert-butyldimethylsilyloxy)-1 -(oxiran-2-yl)pent-4-yn-1-ol (VIII) to a double esterification and to a radicalary cyclization, yielding a compound of formula (V), where either a compound of formula (VIII) is submitted to a first esterification reaction, then to a catalytic radicalary cyclization using titanocene dichloride as catalyst in the presence of Mn/2,4,6-collidine HCI or Zn/2,4,6-collidine/trimethylsilyl chloride, and finally to a second esterification reaction or, alternatively, the compound of formula (VIII) is submitted first to a catalytic radicalary cyclization, and then to an esterification reaction. Entecavir can be obtained by submitting compound (V) to a desilylation reaction to remove the TBS group and then to a Mitsunobu coupling with 2- amino-6-chloroguanine, followed by hydrolysis. It also relates to some new intermediates of the process.
    它包括一种恩替卡韦的制备过程,包括:将(1S, 3R)-3-(叔丁基二甲基氧基)-1-(环氧丙烷-2-基)戊-4-炔-1-醇(VIII)提交给双酯化和自由基环化,得到化合物的公式(V),其中化合物的公式(VIII)被提交给第一酯化反应,然后在Mn/2,4,6-哥林丁盐酸盐或Zn/2,4,6-哥林丁/三甲基氯硅烷的存在下,使用二氯化钛作为催化剂进行催化自由基环化,最后进行第二酯化反应;或者,化合物的公式(VIII)首先被提交给催化自由基环化,然后进行酯化反应。恩替卡韦可以通过将化合物(V)提交给去反应以去除TBS基团,然后与2-基-6-氯鸟嘌呤进行三宅信夫偶联,随后进行解来获得。它还涉及该过程的一些新中间体。
  • Synthesis of β-Hydroxy O-Alkyl Hydroxylamines from Epoxides Using a Convenient and Versatile Two-Step Procedure
    作者:David Crich、Gaëlle Malik、Angélique Ferry、Xavier Guinchard
    DOI:10.1055/s-0032-1317699
    日期:——
    Abstract A simple and convenient synthetic method was developed to prepare β-hydroxy O-alkyl hydroxylamines in which base-mediated ring opening of epoxides with acetophenone oxime followed by cleavage of the oxime with 2,4-dinitrophenylhydrazine in acidic media furnished the hydroxylamine, which can be protected in situ with various N-protecting groups. A simple and convenient synthetic method was
    摘要 开发了一种简单方便的合成方法来制备β-羟基O-烷基羟胺,其中用苯乙酮经碱介导的环氧化物开环,然后在酸性介质中用2,4-二硝基苯裂解,得到羟胺,该羟胺可以被各种N-保护基团原位保护。 开发了一种简单方便的合成方法来制备β-羟基O-烷基羟胺,其中用苯乙酮经碱介导的环氧化物开环,然后在酸性介质中用2,4-二硝基苯裂解,得到羟胺,该羟胺可以被各种N-保护基团原位保护。
  • Removal of Pinanol via Continuous Steam Distillation
    作者:Atul S. Kotnis、Dale Vanyo、Sushil Srivastava、Ambarish K. Singh、Joseph Bush、J. Siva Prasad、Donald C. Kientzler、Edward J. Delaney、San Kiang
    DOI:10.1021/op010209c
    日期:2002.5.1
    A practical procedure for the efficient removal of pinanol from the reaction mixture has been developed. The process was based on the observation that pinanol can be easily removed by steam distillation in the laboratory. On-scale, a continuous counter-current column stripper was implemented to remove pinanol.
    已经开发出一种从反应混合物中有效去除频哪醇的实用程序。该过程基于观察到在实验室中可以通过蒸汽蒸馏轻松去除频醇。在规模上,实施连续逆流柱汽提器以去除松醇。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫